Tyler TX 结直肠癌临床试验
8项针对 结直肠癌的研究正在 Tyler及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #70, Tyler
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
招募中3 期
- Texas Oncology - Northeast Texas, Tyler
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
招募中3 期
- UT Health East Texas HOPE Cancer Center, Tyler
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
招募中3 期
- Texas Oncology, P.A. - Tyler, Tyler
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
招募中3 期
- Clinical Study Site, Tyler
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas at Tyler, Tyler
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
招募中1/2 期
- Texas Oncology, Tyler
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
招募中2 期
- Texas Oncology - Northeast Texas, Tyler
其他城市的 结直肠癌试验
- Houston, TX102 项研究
- New York City, NY78 项研究
- Nashville, TN69 项研究
- Boston, MA63 项研究
- Los Angeles, CA59 项研究
- Arlington, VA52 项研究
- St. Louis, MO50 项研究
- San Antonio, TX46 项研究
- Philadelphia, PA44 项研究
- Grand Rapids, MI40 项研究
- Baldwin Park, CA37 项研究
- Chicago, IL34 项研究
Tyler的其他研究
- 非小细胞肺癌20 项研究
- 克罗恩病17 项研究
- 溃疡性结肠炎15 项研究
- 心力衰竭8 项研究
- 卵巢癌7 项研究
- 癌症（所有类型）7 项研究
- 头颈鳞状细胞癌6 项研究
- 子宫内膜癌6 项研究
- 乳腺癌6 项研究
- 小细胞肺癌5 项研究
- 炎症性肠病5 项研究
- 消化系统疾病5 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。